PTGES3L-AARSD1

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, PTGES3L-AARSD1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PTGES3L-AARSD1 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTGES3L-AARSD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTGES3L-AARSD1 expression acts as an unfavorable survival marker.

HNSC are the cancer types where PTGES3L-AARSD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCDFSMedianAll0.7541.000.0444view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PTGES3L-AARSD1–HNSC (DFS)

Kaplan–Meier survival curve for PTGES3L-AARSD1 mass-spec protein-high vs -low samples in HNSC.

Open the HNSC breakdown →

Exploration